Reviva Announces Grant Of U.S. Patent 12053477 Covering Use Of Brilaroxazine For The Treatment Of Idiopathic Pulmonary Fibrosis
Portfolio Pulse from Benzinga Newsdesk
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced the grant of U.S. Patent 12053477 for the use of brilaroxazine in treating idiopathic pulmonary fibrosis (IPF) and other conditions. The drug has also received Orphan Drug Designation from the FDA.
August 06, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) has been granted a U.S. patent for brilaroxazine, which is used to treat idiopathic pulmonary fibrosis (IPF) and other conditions. The drug has also received Orphan Drug Designation from the FDA.
The grant of a U.S. patent and Orphan Drug Designation for brilaroxazine is a significant milestone for Reviva Pharmaceuticals. This enhances the company's intellectual property portfolio and could lead to increased investor confidence and potential market opportunities.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100